Cutaneous Melanoma Clinical Trials in Boston, Massachusetts

4 studies are recruiting for cutaneous melanoma in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Massachusetts General Hospital, Boston, Massachusetts
    Locations
    57 in total
    Run by
    Guardant Health, Inc.

    See if you can join NCT05059444 on ClinicalTrials.gov

  2. A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

    The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Researchers will comp…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Dana Farber, Boston, Massachusetts
    Locations
    9 in total
    Run by
    Linnaeus Therapeutics, Inc.

    See if you can join NCT06624644 on ClinicalTrials.gov

  3. ACTengine® IMA203 Combined With mRNA-4203

    This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Dana Farber Cancer Institute, Boston, Massachusetts
    Locations
    4 in total
    Run by
    Immatics US, Inc.

    See if you can join NCT06946225 on ClinicalTrials.gov

  4. A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

    This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Massachusetts General Hospital, Boston, Massachusetts
    Locations
    13 in total
    Run by
    GV20 Therapeutics

    See if you can join NCT05669430 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.